Parkinson’s Disease as a Multi-System Disorder

Moving Beyond a Dopamine-Centric Model to Understand Autonomic and Cardiovascular Impact

Timothy Johnson
Founder and Director, Parkinson’s Resilience Institute

March 2026

Abstract

Parkinson’s disease (PD) is most commonly understood as a disorder of dopaminergic neuron loss, producing hallmark motor symptoms such as tremor, rigidity, and bradykinesia. While this model remains clinically important, it is incomplete. A substantial body of research demonstrates that PD involves degeneration across multiple neurotransmitter systems, including norepinephrine, serotonin, and acetylcholine, as well as widespread network dysfunction.

This paper examines the role of non-dopaminergic systems, particularly the noradrenergic system, in autonomic dysfunction, and explores downstream implications for cardiovascular regulation. Reframing PD as a multi-system disorder provides a more accurate understanding of patient experience and supports a broader, more integrated approach to care.

1. Introduction

A 62-year-old patient presents with a three-year history of persistent constipation, intermittent lightheadedness upon standing, disrupted sleep, and increasing anxiety. Over time, additional symptoms emerge: urinary urgency, reduced exercise tolerance, and unexplained fatigue. Evaluations by gastroenterology, cardiology, and primary care providers yield partial explanations but no unifying diagnosis. Symptoms are treated individually as unrelated conditions.

Two years later, a resting tremor appears. Only then does Parkinson’s disease enter the conversation.

This pattern is not unusual.

Parkinson’s disease is most often identified through its motor symptoms – tremor, rigidity, bradykinesia, and postural instability – each closely tied to dopaminergic neuron loss in the substantia nigra. This framework is clinically useful, but it creates a structural limitation: symptoms that fall outside motor control are frequently disconnected from the disease process, particularly in earlier stages.

A growing body of evidence shows that many individuals with PD experience a broad constellation of non-motor symptoms, often years before motor dysfunction becomes apparent (Chaudhuri et al., 2006; Kalia & Lang, 2015). These symptoms are commonly evaluated in isolation and attributed to unrelated conditions.

The result is fragmentation:

  • Symptoms distributed across specialties

  • Treatment approaches focused on isolated systems

  • Delayed recognition of an underlying neurodegenerative process

Parkinson’s disease is not solely a disorder of movement. It is a progressive, multi-system condition involving multiple neurotransmitter systems and regulatory networks. When these systems are considered together, the seemingly unrelated symptoms reported by patients form a coherent and clinically meaningful pattern.

2. Dopaminergic Dysfunction: Central but Not Sufficient

Dopamine depletion remains a defining pathological feature of PD and is directly responsible for its primary motor symptoms. The clinical effectiveness of levodopa and related therapies reinforces the centrality of dopaminergic dysfunction in motor control.

However, dopaminergic treatment does not address the full spectrum of disease expression. Non-motor symptoms frequently persist, and in some cases precede motor manifestations, indicating broader neurobiological involvement (Kalia & Lang, 2015).

3. Noradrenergic Degeneration and the Locus Coeruleus

3.1 Early Involvement in Disease Progression

Neuropathological studies demonstrate that degeneration in PD extends beyond the substantia nigra. Brainstem structures, including the locus coeruleus, the brain’s primary source of norepinephrine, may be affected early in disease progression (Braak et al., 2003).

3.2 Functional Role of Norepinephrine

The noradrenergic system regulates:

  • Blood pressure and heart rate

  • Arousal and alertness

  • Stress response

  • Autonomic coordination

Degeneration within this system contributes to impaired physiological regulation and autonomic instability (Goldstein, 2003; Goldstein, 2014).

4. Autonomic Dysfunction in Parkinson’s Disease

Autonomic dysfunction (dysautonomia) is a common and clinically significant component of PD. Manifestations include:

  • Orthostatic hypotension

  • Supine hypertension

  • Gastrointestinal dysmotility

  • Urinary dysfunction (urgency, frequency, incomplete emptying)

  • Sexual dysfunction (erectile dysfunction, decreased arousal)

  • Impaired thermoregulation

  • Fatigue unrelated to exertion

These symptoms reflect disruption of both central and peripheral autonomic pathways and are associated with impaired catecholaminergic signaling and baroreflex dysfunction (Palma & Kaufmann, 2018).

5. Cardiovascular Implications of Autonomic Dysfunction

5.1 Cardiac Sympathetic Denervation

MIBG imaging studies demonstrate reduced cardiac sympathetic innervation in individuals with PD (Orimo et al., 2005), indicating impaired autonomic input to the heart.

5.2 Brain–Heart Interaction

Disruption of autonomic signaling can result in:

  • Blood pressure variability

  • Altered heart rate variability

  • Palpitations

These effects are best understood as regulatory disturbances rather than primary cardiac pathology in many cases.

5.3 Relationship to Cardiac Rhythm Disturbances

PD does not directly cause arrhythmias such as atrial fibrillation. However, autonomic imbalance may influence cardiac electrophysiology and contribute to symptom variability in susceptible individuals.

6. Expanded Neurotransmitter-Linked Symptomatology

6.1 Dopamine

  • Tremor, rigidity, bradykinesia

  • Postural instability

  • Apathy, reduced motivation

6.2 Norepinephrine

  • Orthostatic hypotension

  • Blood pressure instability

  • Fatigue

  • Reduced stress tolerance

  • Impaired autonomic regulation, including cardiovascular variability

6.3 Acetylcholine

  • Impaired attention and executive function

  • Cognitive slowing

  • Gait and balance disturbances

  • Increased fall risk

(Bohnen & Albin, 2011)

6.4 Serotonin

  • Depression

  • Anxiety

  • Sleep disturbances (including REM sleep behavior disorder)

  • Emotional dysregulation

(Politis & Niccolini, 2015)

6.5 Integrated Autonomic and Neurotransmitter Effects

Many autonomic symptoms reflect overlapping dysfunction across systems:

  • Gastrointestinal slowing

  • Urinary urgency, frequency, and incomplete emptying

  • Sexual dysfunction (erectile dysfunction, decreased libido or arousal)

  • Temperature dysregulation

These symptoms are often among the earliest reported and may precede motor features by years.

7. Clinical Recognition and Diagnostic Implications

7.1 Fragmentation of Early Symptoms

When non-motor symptoms precede motor manifestations, they are frequently evaluated within separate clinical silos:

  • Cardiology: blood pressure variability, palpitations

  • Gastroenterology: constipation, delayed gastric emptying

  • Urology: urinary urgency, frequency, retention

  • Endocrinology or primary care: fatigue

  • Psychiatry: depression, anxiety

  • Sleep medicine: REM sleep disturbances

  • Sexual health: erectile dysfunction or reduced arousal

Without a unifying framework, these symptoms are often treated as independent conditions.

7.2 Risk of Misattribution and Delayed Diagnosis

This fragmentation can lead to:

  • Delayed recognition of Parkinson’s disease

  • Repeated evaluations without diagnostic clarity

  • Treatment strategies that address symptoms but not underlying cause

Patients may experience a prolonged period of uncertainty before motor symptoms prompt neurological evaluation.

7.3 Implications for Specialist Awareness

There is a need to improve awareness among non-neurology specialists regarding the multi-system nature of PD, particularly in:

  • Older adults

  • Patients with clusters of autonomic, sleep, mood, urinary, or sexual symptoms

  • Individuals with persistent, unexplained multi-system complaints

Recognition of symptom patterns—rather than isolated findings—can support earlier identification of underlying neurological disease.

7.4 Toward Coordinated, Multi-Disciplinary Recognition

Earlier identification of Parkinson’s disease depends on recognizing patterns that span specialties and systems. This requires a more coordinated clinical perspective in which neurologists, cardiologists, gastroenterologists, urologists, psychiatrists, and primary care providers share a common framework for interpreting multi-system symptoms.

A multi-disciplinary approach does more than broaden awareness—it creates the conditions for earlier pattern recognition, more accurate diagnosis, and more effective, integrated care.

8. Discussion

The traditional dopamine-centric model of Parkinson’s disease has provided a clear and effective framework for addressing motor symptoms. However, it does not fully account for the breadth, timing, or variability of non-motor manifestations.

A multi-system model offers several advantages:

  • It explains early, non-motor symptom presentation

  • It accounts for variability across patients

  • It supports more integrated clinical management

  • It reduces the likelihood of fragmented care

From a patient perspective, this model resolves a common experience: the sense that multiple, seemingly unrelated symptoms are occurring without explanation. From a clinical perspective, it provides a more accurate representation of disease progression and system-level dysfunction.

9. Conclusion

Parkinson’s disease is a multi-system neurodegenerative disorder involving dopaminergic, noradrenergic, cholinergic, serotonergic, and broader network-level dysfunction. While dopamine loss drives the hallmark motor symptoms, disruption across additional systems contributes significantly to autonomic, cognitive, emotional, urinary, and sexual manifestations.

Recognizing these interconnected systems transforms how the disease is understood and managed. It enables earlier identification, supports multidisciplinary care, and provides a more coherent framework for both clinicians and patients navigating the complexity of Parkinson’s disease.

About the Author

Timothy Johnson is founder of the Parkinson’s Resilience Institute. His work focuses on developing structured resilience programs and support models for people living with Parkinson’s disease and their caregivers.

References

  • Bohnen, N. I., & Albin, R. L. (2011). The cholinergic system and Parkinson disease. Behavioral Brain Research, 221(2), 564–573.

  • Braak, H., Del Tredici, K., Rüb, U., et al. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211.

  • Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. V. (2006). Non-motor symptoms of Parkinson’s disease. The Lancet Neurology, 5(3), 235–245.

  • Goldstein, D. S. (2003). Dysautonomia in Parkinson’s disease.

  • Goldstein, D. S. (2014). The extended autonomic system in Parkinson disease. Clinical Autonomic Research, 24(1), 1–7.

  • Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912.

  • Orimo, S., Ozawa, E., Nakade, S., et al. (2005). (123)I-MIBG myocardial scintigraphy in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 76(5), 683–688.

  • Palma, J.-A., & Kaufmann, H. (2018). Treatment of autonomic dysfunction in Parkinson disease. Current Treatment Options in Neurology, 20(8).

  • Politis, M., & Niccolini, F. (2015). Serotonin in Parkinson’s disease. Behavioural Brain Research, 277, 136–145.

Download PDF